Close X

Attorney Spotlight

How does Eli Richardson's past work with the federal government inform his client interactions? Find out more>

Search

Close X

Experience

Search our Experience

Experience Spotlight

In June 2016, AmSurg Corp. and Envision Healthcare Holdings, Inc. (Envision) announced they have signed a definitive merger agreement pursuant to which the companies will combine in an all-stock transaction. Upon completion of the merger, which is expected to be tax-free to the shareholders of both organizations, the combined company will be named Envision Healthcare Corporation and co-headquartered in Nashville, Tennessee and Greenwood Village, Colorado. The company's common stock is expected to trade on the New York Stock Exchange under the ticker symbol: EVHC. Bass, Berry & Sims served as lead counsel on the transaction, led by Jim Jenkins. Read more.

AmSurg logo


Close X

Thought Leadership

Enter your search terms in the relevant box(es) below to search for specific Thought Leadership.
To see a recent listing of Thought Leadership, click the blue Search button below.

Thought Leadership Spotlight

Inside the FCA blogInside the FCA blog features ongoing updates related to the False Claims Act (FCA), including insight on the latest legal decisions, regulatory developments and FCA settlements. The blog provides timely updates for corporate boards, directors, compliance managers, general counsel and other parties interested in the organizational impact and legal developments stemming from issues potentially giving rise to FCA liability.

Read More >

Medico-Legal Ethics of Off-Label Use of Pharmaceuticals and Devices

Events

May 8, 2012

Bass, Berry & Sims healthcare attorneys John Kelly and Danielle Sloane will present the topic "Medico-Legal Ethics of Off-Label Use of Pharmaceuticals and Devices," at an upcoming Nashville Council of Health Care Attorneys (NCHCA) meeting. This presentation will include:

  • Overview of what constitutes off label use versus off label promotion and why physicians prescribe off-label;
  • Government recent enforcement of off-label promotion violations;
  • The pharmaceutical and device companies attempting to limit the FDA's reach with the first amendment;
  • FDA response to industry requests for additional clarity on when it is permissible for pharmaceutical and device companies to distribute information regarding off-label uses; and
  • An ethical debate and evaluation of competing interests: regulatory oversight versus off-label promotion and use.

This course has been approved for one hour of dual CLE credit.


In Case You Missed It:

Related Professionals

Related Services

Notice

Visiting, or interacting with, this website does not constitute an attorney-client relationship. Although we are always interested in hearing from visitors to our website, we cannot accept representation on a new matter from either existing clients or new clients until we know that we do not have a conflict of interest that would prevent us from doing so. Therefore, please do not send us any information about any new matter that may involve a potential legal representation until we have confirmed that a conflict of interest does not exist and we have expressly agreed in writing to the representation. Until there is such an agreement, we will not be deemed to have given you any advice, any information you send may not be deemed privileged and confidential, and we may be able to represent adverse parties.